The whole blood is added to QScout to run the test and the results are displayed in about two minutes. Image Credit: Tan_supa / Shutterstock.

Ad Astra Diagnostics has received 510(k) clearance from the US Food and Drug Administration (FDA) for its point-of-care QScout rapid-result haematology system.

The results generated by the QScout system include white blood cell counts (WBCs) and neutrophil-to-lymphocyte ratio, as well as differentiate the number and per cent of five types of mature WBCs, along with immature granulocytes (IGs).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

These blood counts can be used to inform the diagnosis of various diseases, including infection, leukaemia, and other blood-related cancers. Furthermore, elevated levels of IGs can be used to differentiate sepsis.

The use of point-of-care diagnostics has increased following the Covid-19 pandemic. The global market for haematology analysers is forecasted to be worth approximately $2.1bn in 2030, as per a GlobalData market model.

The whole blood is added to QScout to run the test, which contains a dried reagent that stains cells. When the test is inserted in the QScout analyser, an optical system takes images, and an algorithm identifies the cells in real-time, with results displayed in about two minutes.

The QScout has been developed with seed funding from the US Biomedical Advanced Research and Development Authority (BARDA), which is a part of Administration for Strategic Preparedness and Response within the US Department of Health and Human Services.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In August, BARDA awarded a contract to Satio to develop a new single-use and patch-based ebolavirus diagnostic. The diagnostic will integrate the patch-based blood collection device of Satio with the Institut Pasteur de Dakar’s sensitive ebolavirus immunoassay within a single device.

In other blood test development news, Jana Care raised $6m in the Series B financing round to complete the commercialisation of its self-administered blood tests for kidney and heart disease last month. In August, Nightingale Health introduced a remote blood collection kit for its medical research and clinical trial customers. The Nightingale kit and self-collection device would allow trial participants to draw their blood samples from a finger-prick.